Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Oncalis and ChemDiv Tackle Cancer-related Kinase Targets

  • Oncalis and ChemDiv entered into an R&D collaboration to discover candidates inhibiting receptor tyrosine kinase and other cancer-related targets. Oncalis will apply its yeast cell-based technology and develop biological assays, and ChemDiv will apply its medicinal chemistry and in vitro and in vivo biology services.

    ChemDiv provided the source for leads to the yeast-based screening platform that is now completely acquired by Oncalis, together with a high-throughput screening platform and IP rights on research projects.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »